PMID- 34311965
OWN - NLM
STAT- MEDLINE
DCOM- 20220801
LR  - 20221207
IS  - 0013-7006 (Print)
IS  - 0013-7006 (Linking)
VI  - 48
IP  - 4
DP  - 2022 Aug
TI  - [Antidepressive agents and hypertension: A case/no-case study in French 
      pharmacovigilance database].
PG  - 404-408
LID - S0013-7006(21)00155-X [pii]
LID - 10.1016/j.encep.2021.04.009 [doi]
AB  - INTRODUCTION: Drug-induced hypertension was described with several 
      pharmacological classes. The association between hypertension and antidepressant 
      drugs (AD) is controversial. The objective of this study was to evaluate the link 
      between hypertension and ADs. MATERIALS AND METHODS: A retrospective 
      disproportionality analysis from observations consecutively reported to the 
      French pharmacovigilance database between 1985 and 2020 was performed. The 
      relationship between the suspected ADs and the occurrence of hypertension was 
      assessed by calculating the reporting odds ratio (ROR) in a case/non-case design. 
      A negative (paracetamol) and a positive (celecoxib) control were used to 
      validated this disproportionality method. RESULTS: We compared 6725 cases 
      (including 464 AD-related cases) to 789,483 non-cases (including 
      56,440 AD-related cases). The reporting of hypertension was significantly 
      associated with serotonin/norepinephrine reuptake inhibitors (SNRI) (ROR 1.43, 
      95 % CI 1.26-1.64) and monoamine oxidase inhibitors (MAOI) (ROR 6.41, 95 % CI 
      4.25-9.67) but not with other ADs classes. Concerning ADs analyzed independently 
      of their AD class, a significant signal was observed with many SNRIs (duloxetin, 
      milnacipran and venlafaxin) and with all MAOIs (moclobemide, iproniazide) (ROR 
      between 2.04 and 17.93) but not with others ADs. The ROR value of positive 
      (celecoxib) and negative (paracetamol) controls were ROR=1.53; 
      IC95 %=1.04-2.26 and ROR=0.72; IC95 %=0.65-0.80, respectively. CONCLUSION: We 
      found a significant association between development or worsening of hypertension 
      and SNRIs and MAOIs but not with others ADs, in this study performed in real 
      conditions of life. It is therefore advisable to remain cautious when prescribing 
      ADs and to check systematically for hypertension.
CI  - Copyright (c) 2021 L'Encephale, Paris. Published by Elsevier Masson SAS. All rights 
      reserved.
FAU - Hofferer, A
AU  - Hofferer A
AD  - Departement de medecine generale, UFR Sante, Normandie Universite, 2, rue des 
      Rochambelles, 14032 Caen cedex 5, France.
FAU - Dolladille, C
AU  - Dolladille C
AD  - Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de 
      pharmacologie clinique, CHU Caen Normandie, Caen, France.
FAU - Chretien, B
AU  - Chretien B
AD  - Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de 
      pharmacologie clinique, CHU Caen Normandie, Caen, France.
FAU - Sassier, M
AU  - Sassier M
AD  - Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de 
      pharmacologie clinique, CHU Caen Normandie, Caen, France.
FAU - Laugier, D
AU  - Laugier D
AD  - Centre regional de pharmacovigilance de Marseille, Marseille, France.
FAU - Atzenhoffer, M
AU  - Atzenhoffer M
AD  - Centre regional de pharmacovigilance de Rhone-Alpes, Lyon, France.
FAU - Bagheri, H
AU  - Bagheri H
AD  - Centre regional de pharmacovigilance de Midi Pyreneens, Toulouse, France.
FAU - Alexandre, J
AU  - Alexandre J
AD  - Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de 
      pharmacologie clinique, CHU Caen Normandie, Caen, France.
FAU - Fedrizzi, S
AU  - Fedrizzi S
AD  - Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de 
      pharmacologie clinique, CHU Caen Normandie, Caen, France.
FAU - Humbert, X
AU  - Humbert X
AD  - Departement de medecine generale, UFR Sante, Normandie Universite, 2, rue des 
      Rochambelles, 14032 Caen cedex 5, France. Electronic address: 
      xavier.humbert@unicaen.fr.
LA  - fre
PT  - Journal Article
TT  - Antidepresseurs et hypertension arterielle : etude cas /non-cas dans la base 
      nationale de pharmacovigilance.
DEP - 20210724
PL  - France
TA  - Encephale
JT  - L'Encephale
JID - 7505643
RN  - 0 (Antidepressive Agents)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Serotonin and Noradrenaline Reuptake Inhibitors)
RN  - 362O9ITL9D (Acetaminophen)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Acetaminophen
MH  - Adverse Drug Reaction Reporting Systems
MH  - Antidepressive Agents/adverse effects
MH  - Celecoxib
MH  - Humans
MH  - *Hypertension/chemically induced/epidemiology
MH  - Monoamine Oxidase Inhibitors/adverse effects
MH  - Pharmacovigilance
MH  - Retrospective Studies
MH  - Selective Serotonin Reuptake Inhibitors
MH  - *Serotonin and Noradrenaline Reuptake Inhibitors
OTO - NOTNLM
OT  - Adverse effects
OT  - Antidepressant agents
OT  - Antidepresseurs
OT  - Effets indesirables
OT  - Hypertension
OT  - Pharmacovigilance
EDAT- 2021/07/28 06:00
MHDA- 2022/08/02 06:00
CRDT- 2021/07/27 05:50
PHST- 2020/06/20 00:00 [received]
PHST- 2021/04/16 00:00 [revised]
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2022/08/02 06:00 [medline]
PHST- 2021/07/27 05:50 [entrez]
AID - S0013-7006(21)00155-X [pii]
AID - 10.1016/j.encep.2021.04.009 [doi]
PST - ppublish
SO  - Encephale. 2022 Aug;48(4):404-408. doi: 10.1016/j.encep.2021.04.009. Epub 2021 
      Jul 24.